An index to identify stroke-related vs incidental patent foramen ovale in cryptogenic stroke
Citation Manager Formats
Make Comment
See Comments

Article Information
- Received December 12, 2012
- Accepted in final form April 29, 2013
- First Published July 17, 2013.
Article Versions
- Previous version (July 17, 2013 - 13:00).
- You are viewing the most recent version of this article.
Author Disclosures
- David M. Kent, MD, CM, MSc,
- Robin Ruthazer, MPH,
- Christian Weimar, MD,
- Jean-Louis Mas, MD,
- Joaquín Serena, MD, PhD,
- Shunichi Homma, MD,
- Emanuele Di Angelantonio, MD, MSc,
- Marco R. Di Tullio, MD,
- Jennifer S. Lutz, MS,
- Mitchell S.V. Elkind, MD, MS,
- John Griffith, PhD,
- Cheryl Jaigobin, MD, MSc,
- Heinrich P. Mattle, MD,
- Patrik Michel, MD,
- Marie-Louise Mono, MD,
- Krassen Nedeltchev, MD,
- Federica Papetti, MD and
- David E. Thaler, MD, PhD
- David M. Kent, MD, CM, MSc,
NONE
NONE
NONE
NONE
NONE
NONE
NONE
WL Gore Associates
NONE
NONE
NONE
NONE
(1)National Institute of Health (NIH), R21 NS079826, Principal Investigator, 2012 to 2014 (2) National Institute of Health (NIH), R01 NS062153, Principal Investigator, 2009 to 2014 (3)Patient Centered Outcomes Research Institute (PCORI) 1IP2PI000722, Principal Investigator, 2012 to 2014
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
- Robin Ruthazer, MPH,
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NIH/NINDS R01 NS062153 The Risk of Paradoxical Embolism (RoPE) Study [PI=Kent] My role: Statistician/Programmer 03/06/09-02/28/14
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
- Christian Weimar, MD,
(1) Bayer Schering (2) Bristol-Myers Squib (3) Sanofi Aventis
NONE
(1) Sanofi Aventis, travel and speaker honoraria (2) Arbeitsgemeinschaft Neurologische Intensivmedizin, funding for travel (3) Deutsche Gesellschaft für Neurologie, funding for travel (4) Biogen Idec, funding for travel (5) Teva, funding for travel (6) Boehringer Ingelheim, funding for travel
(1) Cerebrovascular Diseases, editorial board member, 2008-ongoing (2) Stroke News, editorial office 2006- ongoing
NONE
NONE
Consultant, University hospital Essen
NONE
(1) Sanofi Aventis (2) Boehringer Ingelheim
participation in clinical trials by (1) Brainsgate, (2) D-Pharm (3) PhotoThera (4) Portola (5) Pierre Fabre
NONE
(1) Johnson & Johnson
(1) German Research Council, 2010-ongoing, WE 2858/3-1 (2) TeBiKom.Ruhr, 2012-ongoing, 005-GW02-067E
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
- Jean-Louis Mas, MD,
(1) Astra-Zeneca (2) Boehringer-Ingelheim (3) BMS (4) Daiichi-Sankyo (5) Sanofi Aventis
NONE
1) Boehringer-Ingelheim, honoraria, 2) Sanofi Aventis, honoraria, 3) Servier, honoraria
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
(1) French Ministry of Health, 1 grant, coordination of a randomized clinical trial, ongoing, (2) INSERM Institut National Scientifique Et de la Recherche Medicale, financing a Stroke Research Unit, ongoing
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
- Joaquín Serena, MD, PhD,
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
- Shunichi Homma, MD,
St Judes - Medical Consultant Pfizer - Pharmaceutical Consultant/Advisory Bd Tekeda - Pharmaceutical Consultant/Advisory Bd BMS - Pharmaceutical Consultant/Advisory Bd
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NIH WARCEF Study, NIH-NINDS, U01 NS043975
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
- Emanuele Di Angelantonio, MD, MSc,
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
- Marco R. Di Tullio, MD,
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NIH/NINDS R01 NS36286-11 PI Years:2005-2012
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
- Jennifer S. Lutz, MS,
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
- Mitchell S.V. Elkind, MD, MS,
(1) Jarvik Heart, Clinical Events Committee member, adjudicating events in clinical trial of artificial heart (2008-present); (2) Biogen IDEC, scientific advisory board, stroke trial design
NONE
NONE
(1) Neurology, Resident and Fellow Section editor, published by American Academy of Neurology (2007-present)
NONE
NONE
Columbia University
(1) BMS-Pfizer Partnership, consultant regarding antithrombotics for stroke
NONE
NONE
NONE
(1) diaDexus, Inc: funding for biomarker research; (2) BMS-Sanofi Pharmaceutical Partnership: funding for biomarker research
(1) NIH/NINDS P50 NS049060, Project PI, 2004-2013;(2) NIH/NINDS R37 NS029993, Co-PI, 2008-2013; (3) NIH/NINDS 1R25 NS070697, PI, 2010-2015
NONE
(1) American Heart Association Founders Affiliate Board of Directors)(2008-present); (2) American Heart Association NY City Board of Directors (2011-present)
NONE
NONE
NONE
NONE
NONE
(1) GSK, Avandia and stroke litigation, 2009-2011;(2) Organon/Merck, NuvaRing and stroke litigation, 2009-present;(3) Novartis, aliskiren and stroke litigation, 2013-present
- John Griffith, PhD,
NONE
NONE
NONE
NONE
NONE
NONE
Northeastern University, Bouve College Associate Dean of Research
NONE
NONE
NONE
NONE
NONE
(1) Boston Public Health Commission. Biostatistician, 2011- 2013 (2) NIH, P50HL105185, Biostatistician, 2010-2015 (3) NIH, R01NS062153, Biostatistician, 2009-2014 (4) NIH, R01MH096707, Biostatistician, 2012-2015
Tufts Medical Center, Biostatistician -2012
NONE
NONE
NONE
NONE
NONE
NONE
NONE
- Cheryl Jaigobin, MD, MSc,
NONE
NONE
NONE
NONE
NONE
NONE
Honoria at speaking engagements sponsored by Boeringer- Ingelheim and Sanofi Aventis June 2008, June 2009
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
- Heinrich P. Mattle, MD,
Servier, St. Jude Medical
NONE
Servier, Sanofi, Bayer, Biogen, Böhringer-Ingelheim, Merck, MSD, Teva, St. Jude Medical, Novartis, Pfizer
Stroke, International Journal of Stroke, Swiss Medical Weekly, Practical Neurology
NONE
Neurologie, Kurzlehrbuch Neurologie, Neurology, Fundamentals of Neurology, DGN Leitlinien, all Thieme Publisher, Stuttgart
NONE
Servier, Sanofi, Bayer, Biogen, Genzyme, Merck, MSD, Pfizer, Teva, AGA Medical, Novartis, Pfizer
Servier, Sanofi, Bayer, Biogen, Merck, Teva, St. Jude Medical, Novartis, Böhringer-Ingelheim
NONE
NONE
Servier, Sanofi, Bayer, Biogen, Merck, Teva, St. Jude Medical, Novartis, Pfizer
Swiss Science Foundation
NONE
Swiss Heart Foundation
NONE
NONE
NONE
NONE
NONE
NONE
- Patrik Michel, MD,
Bayer, Pfizer
NONE
Bayer, Boehringer-Ingelheim
International Journal of Stroke.
NONE
NONE
NONE
Pierre-Fabre
Boehringer-Ingelheim, Bayer
NONE
NONE
Lundbeck
Swiss National Science Foundation
NONE
Swiss Cardiology Foundation
NONE
NONE
NONE
NONE
NONE
NONE
- Marie-Louise Mono, MD,
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
- Krassen Nedeltchev, MD,
Served on a scientific advisory board for Bayer (Schweiz) AG, Pfizer, Boehringer-Ingelheim, Teva Pharmaceuticals, Genzyme
NONE
NONE
NONE
NONE
NONE
NONE
Consultancies for “Innovative Technologies-Invatec” in 2007.
NONE
NONE
NONE
NONE
Sponsor/Funding source: The Swiss National Research Foundation, Grant Nr 32003B_120522; 3 years
NONE
Swiss Heart Foundation
NONE
NONE
NONE
NONE
NONE
NONE
- Federica Papetti, MD and
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
- David E. Thaler, MD, PhD
Lantheus Medical Imaging, DSMB
NONE
NONE
NONE
NONE
NONE
NONE
St Jude Medical (AGA Medical); WL Gore Associates
NONE
NONE
NONE
NONE
NINDS, Risk of Paradoxical Embolism (RoPE) Study, co-PI
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
- From the Institute for Clinical Research and Health Policy Studies (D.M.K., R.R., J.S.L., J.G.) and Department of Neurology (D.M.K., D.E.T.), Tufts Medical Center/Tufts University School of Medicine, Boston, MA; Department of Neurology (C.W.), University of Duisburg-Essen, Germany; Department of Neurology (J.-L.M.), Hôpital Sainte-Anne, Paris-Descartes University, France; Department of Neurology (J.S.), Hospital Universitari Doctor Josep Trueta Institut d'Investigació Biomèdica de Girona, Spain; Division of Cardiology (S.H., M.R.D.) and Departments of Neurology (M.S.V.E.) and Epidemiology (M.S.V.E.), Columbia University, New York, NY; Department of Public Health and Primary Care (E.D.), Cambridge University, UK; Department of Neurology (C.J.), University of Toronto, Canada; Department of Neurology (H.P.M., M.-L.M.), Inselspital, University of Bern; Centre Hospitalier Universitaire de Lausanne (P.M.); Department of Neurology (K.N.), Triemli Municipal Hospital, Switzerland; and Department of Cardiology (F.P.), Sapienza University of Rome, Italy.
- Correspondence to Dr. Kent: Dkent1{at}tuftsmedicalcenter.org
Article usage
Letters: Rapid online correspondence
REQUIREMENTS
You must ensure that your Disclosures have been updated within the previous six months. Please go to our Submission Site to add or update your Disclosure information.
Your co-authors must send a completed Publishing Agreement Form to Neurology Staff (not necessary for the lead/corresponding author as the form below will suffice) before you upload your comment.
If you are responding to a comment that was written about an article you originally authored:
You (and co-authors) do not need to fill out forms or check disclosures as author forms are still valid
and apply to letter.
Submission specifications:
- Submissions must be < 200 words with < 5 references. Reference 1 must be the article on which you are commenting.
- Submissions should not have more than 5 authors. (Exception: original author replies can include all original authors of the article)
- Submit only on articles published within 6 months of issue date.
- Do not be redundant. Read any comments already posted on the article prior to submission.
- Submitted comments are subject to editing and editor review prior to posting.
You May Also be Interested in
Hastening the Diagnosis of Amyotrophic Lateral Sclerosis
Dr. Brian Callaghan and Dr. Kellen Quigg
► Watch
Related Articles
Alert Me
Recommended articles
-
Articles
Recurrent cerebral ischemia in medically treated patent foramen ovaleA meta-analysisM. A. Almekhlafi, S. B. Wilton, D. M. Rabi et al.Neurology, May 13, 2009 -
Article
Percutaneous patent foramen ovale closure for secondary stroke preventionNetwork meta-analysisGeorgios Tsivgoulis, Aristeidis H. Katsanos, Dimitris Mavridis et al.Neurology, June 06, 2018 -
Special Article
Practice advisory update summary: Patent foramen ovale and secondary stroke preventionReport of the Guideline Subcommittee of the American Academy of NeurologySteven R. Messé, Gary S. Gronseth, David M. Kent et al.Neurology, April 29, 2020 -
Article
Recurrent stroke predictors differ in medically treated patients with pathogenic vs other PFOsDavid E. Thaler, Robin Ruthazer, Christian Weimar et al.Neurology, June 13, 2014